WATME-specific immunotherapy for obesity-induced coronary heart disease (CHD)
Schematic diagram of WATME-specific immunotherapy for obesity-induced coronary heart disease (CHD). Obesity is associated with increased secretion of pro-inflammatory cytokines, especially IL-1β, TNF-α, and IL-6, by obese WATME. There is established evidence linking these cytokines to the occurrence of atherosclerosis. Several WATME-specific immunotherapies have been identified for the treatment of atherosclerosis-mediated development of obesity-induced CHD. These WATME-specific immunotherapies target the NLRP3 inflammasome, TNF-α, and inflammatory signaling pathways. Some examples are Bazedoxifene and Etanercept
Publication
Immunotherapy targeting the obese white adipose tissue microenvironment: Focus on non-communicable diseases (2024) Lia Priscilla, et al. Bioact Mater. 2024 May;35(NA). Figure: F5.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | NLRP3 | NLRP3 | ncbigene_symbol | NLRP3 | 114548 |
| Homo sapiens | Primates | AMPK | AMPK | ncbigene_synonym | PRKAA1 | 5562 |
| Homo sapiens | Primates | AMPK | AMPK | ncbigene_synonym | PRKAA2 | 5563 |
| Homo sapiens | Primates | AMPK | AMPK | ncbigene_synonym | PRKAB1 | 5564 |
| Homo sapiens | Primates | AMPK | AMPK | famplex_relations | PRKAB2 | 5565 |
| Homo sapiens | Primates | AMPK | AMPK | famplex_relations | PRKAG1 | 5571 |
| Homo sapiens | Primates | AMPK | AMPK | famplex_relations | PRKAG2 | 51422 |
| Homo sapiens | Primates | AMPK | AMPK | famplex_relations | PRKAG3 | 53632 |
| Homo sapiens | Primates | AKT/AMPK/NLRP3 | AKT | ncbigene_synonym | AKT1 | 207 |
| Homo sapiens | Primates | AKT/AMPK/NLRP3 | AKT | famplex_relations | AKT2 | 208 |
| Homo sapiens | Primates | AKT/AMPK/NLRP3 | AKT | famplex_relations | AKT3 | 10000 |
| Homo sapiens | Primates | IFN-B | IFN-B | ncbigene_synonym | IFNB1 | 3456 |
| Homo sapiens | Primates | IRF3 | IRF3 | ncbigene_symbol | IRF3 | 3661 |
| Homo sapiens | Primates | TLR4/Trif/IRF3/IFN-B | TRIF | ncbigene_synonym | TRIM69 | 140691 |
| Homo sapiens | Primates | TLR4/Trif/IRF3/IFN-B | TRIF | ncbigene_synonym | TICAM1 | 148022 |
| Homo sapiens | Primates | TLR4/Trif/IRF3/IFN-B | TLR4 | ncbigene_symbol | TLR4 | 7099 |
| Homo sapiens | Primates | NF-kB | NF-KB | ncbigene_synonym | NFKB1 | 4790 |
| Homo sapiens | Primates | IL-1R | IL1R | ncbigene_synonym | IL1R1 | 3554 |
| Homo sapiens | Primates | TNF-a | TNF-A | ncbigene_synonym | TNF | 7124 |
| Homo sapiens | Primates | PCSK9 | PCSK9 | ncbigene_symbol | PCSK9 | 255738 |
| Homo sapiens | Primates | ApoB100 | APOB100 | ncbigene_synonym | APOB | 338 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| TNF-a | TNF-a | chebi:197439 | ||
| Canagliflozin | canagliflozin | (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol--water (2/1) | chebi:73272 |